JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Use of CRP/lymphocyte ratio as a predictor of treatment selection and mortality in COVID-19 patients in the intensive care unit

  • 0Department of Chest Diseases, Cukurova University, Adana, Turkey.
International Journal of Immunopathology and Pharmacology +

|

December 19, 2024

|

December 19, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

The C-reactive protein to lymphocyte ratio (CLR) can predict mortality in critically ill COVID-19 patients. Higher CLR levels indicate a greater risk of death, guiding intensive monitoring and treatment adjustments for better patient outcomes.

Area Of Science

  • Critical Care Medicine
  • Inflammation Biomarkers
  • Infectious Diseases

Background

  • COVID-19 patients admitted to the ICU experience significant mortality.
  • Inflammation markers are crucial for assessing disease severity and prognosis.
  • The C-reactive protein to lymphocyte ratio (CLR) is a potential indicator of systemic inflammation.

Purpose Of The Study

  • To investigate the prognostic value of the C-reactive protein to lymphocyte ratio (CLR) in intensive care unit (ICU) patients with COVID-19.
  • To determine the association between CLR and disease progression, including mortality risk.
  • To identify an optimal CLR threshold for predicting adverse outcomes in severe COVID-19.

Main Methods

  • Retrospective analysis of 464 COVID-19 patients admitted to the ICU.
  • Collection of sociodemographic, laboratory, radiological, and clinical data.
  • Comparison of CLR values between survivors and non-survivors, and correlation with mortality risk factors.

Main Results

  • The overall mortality rate in the cohort was 42%.
  • High-flow oxygen, mechanical ventilation, SOFA Score, Charlson Comorbidity Index, and Nutric Score were associated with increased mortality risk.
  • An optimal CLR threshold of 103.05 was identified, with values above this significantly increasing the risk of death (1.84 times).

Conclusions

  • The C-reactive protein to lymphocyte ratio (CLR) is a valuable, accessible, and cost-effective biomarker for predicting mortality in critically ill COVID-19 patients.
  • Elevated CLR levels necessitate intensified monitoring and prompt treatment modifications.
  • CLR can aid in the management of severe COVID-19 and other aggressive inflammatory diseases.

Keywords: